Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. (1st December 2016)

• Record Type: Journal Article
• Authors: Cimmaruta, D; Maiorino, MI; Scavone, C; Sportiello, L; Rossi, F; Giugliano, D; Esposito, K; Capuano, A
• Is Part Of: Expert opinion on drug safety. Volume 15(2016)Supplement 2
• Page Start: 77
• Page End: 83
• Publication Date: 2016-12-01
• Subjects: GLP-1 RA insulin combination -- HbA1c levels -- hypoglycemia -- type 2 diabetes mellitus; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2016.1221402
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction: Attaining optimal glycemic targets in patients with type 2 diabetes is often hard and compromised by the shortcomings of the several treatments. Areas covered: When glycemic levels are not adequately controlled, an association of GLP-1 receptor agonists and insulin therapy can be adopted. In order to assess the benefit/risk profile of this combination therapy, a literature search of randomized clinical trials was performed.Eighteen trials matched the inclusion criteria. In 10 studies, GLP-1 receptor agonists were added on to an existing regimen, whereas insulin added to an existing GLP-1 receptor agonists regimen occurred in 2 studies. Six studies compared GLP-1 receptor agonists with short acting insulin as a treatment strategy to intensify basal insulin therapy. Expert opinion: Clinical trials herein reviewed demonstrated the safety and the efficacy of combining GLP-1 receptor agonists with basal insulin, with most studies showing equal or slightly superior efficacy, as compared with the addition of prandial insulin, associated with weight loss and less hypoglycemia.